FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2400666686> ?p ?o ?g. }

• W2400666686 endingPage "01" @default.
• W2400666686 startingPage "P6" @default.
• W2400666686 abstract "Abstract Introduction HER2+ MBC patients with CNS metastases are often excluded from clinical trials. The Systemic Therapies for HER2+ Metastatic Breast Cancer Registry (SystHERs), a real-world, prospective registry study, is uniquely positioned to evaluate this understudied population over time. Here we describe the clinical characteristics, HER2-targeted treatments, and survival outcomes of patients with and without CNS metastases at MBC diagnosis. Methods SystHERs is enrolling patients with HER2+ MBC who are &gt;18 years of age and within 6 months of MBC diagnosis. Patients with CNS metastases are identified by their physicians according to local clinical practice. Patient-reported outcomes are obtained at enrollment and throughout the study. Median PFS and OS were estimated using the Kaplan-Meier method and Cox regressions were used to estimate hazard ratios (HRs). Results As of February 2, 2015, data are available for 579 eligible patients, of whom 53 (9%) had CNS metastases at MBC diagnosis (median time from diagnosis to enrollment was 2.3 months). Clinical characteristics and patient-reported functioning in patients with and without CNS metastases at MBC diagnosis are shown in Table 1. Table 1. CNS (n=53)Non-CNS (n=526)Median age (range)57 (36-86)56 (21-88)De novo MBCa, n (%)15 (28)275 (52)Hispanic or Latina, n (%)7 (13)52 (10)White, n (%)46 (87)407 (77)BMI (range)29 (17-43)28 (9-60)ECOG PS (0-1), n (%)36 (68)471 (90)Hormone receptor status, n (%) ER+,PR+21 (40)247 (47)ER+,PR-11 (21)106 (20)ER-,PR+010 (2)ER-, PR-21 (40)153 (29)FACT-Bb,c, median (IQR)(n=42)(n=422) 93 (78-110)102 (85-118)Rotterdam Symptom Checklistb,d, median (IQR)(n=43)(n=429) 75 (54-88)88 (67-100)General HRQOLb,d, median (IQR)(n=43)(n=434) 60 (50-80)80 (61-90)aMetastases confirmed within approximately 90 days of diagnosis. bHigher scores indicate better functioning. cScale range 0-144. dScale range 0-100. First-line MBC treatment data are available for 502 patients, of whom 488 (97%) reported first-line HER2-targeted therapy at the time of data cutoff (Table 2). Table 2.First-line HER2-targeted therapy, n (%)CNS (n=40)Non-CNS (n=448)Any trastuzumab + pertuzumab22 (55)313 (70)Any trastuzumab, no pertuzumab11 (28)117 (26)Any lapatinib14 (35)14 (3)Any T-DM15 (13)29 (6) At a median follow-up time of 12.9 months, median first PFS was 8 months in patients with CNS metastases, and 11.9 months in those without (HR = 0.442; 95% CI 0.304 – 0.641). Median OS was 22 months in patients with CNS metastases, and was not reached in patients without CNS metastases (HR = 0.299; 95% CI 0.174 – 0.514). Conclusions Patients with CNS metastases at MBC diagnosis represent 9% of this registry population. Poor baseline function and an increased risk of progression and death characterized these patients compared to those without baseline CNS metastases. Treatments administered to these patients differ from ASCO consensus recommendations (Ramakrishna, 2014). Further studies are needed to determine the associations between treatments and both clinical and patient-reported outcomes. At the time of presentation, detailed treatment data and additional patient-reported data will be available. Citation Format: Cobleigh M, Hurvitz S, O'Shaughnessy J, Mason G, Yardley D, Jahanzeb M, Brufsky A, Rugo H, Swain S, Kaufman P, Tripathy D, Mayer M, Ogale S, Yoo B, Beattie M. Central nervous system metastases at diagnosis in patients with HER2+ MBC: Baseline characteristics, HER2-targeted treatments and clinical outcomes from the SystHERs registry. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-17-01." @default.
• W2400666686 created "2016-06-24" @default.
• W2400666686 creator A5006757571 @default.
• W2400666686 creator A5010529280 @default.
• W2400666686 creator A5021270265 @default.
• W2400666686 creator A5023674071 @default.
• W2400666686 creator A5026987682 @default.
• W2400666686 creator A5043219897 @default.
• W2400666686 creator A5048774512 @default.
• W2400666686 creator A5049168429 @default.
• W2400666686 creator A5049358292 @default.
• W2400666686 creator A5051465568 @default.
• W2400666686 creator A5053164536 @default.
• W2400666686 creator A5058128666 @default.
• W2400666686 creator A5067203408 @default.
• W2400666686 creator A5068075658 @default.
• W2400666686 creator A5089332843 @default.
• W2400666686 date "2016-02-15" @default.
• W2400666686 modified "2023-10-02" @default.
• W2400666686 title "Abstract P6-17-01: Central nervous system metastases at diagnosis in patients with HER2+ MBC: Baseline characteristics, HER2-targeted treatments and clinical outcomes from the SystHERs registry" @default.
• W2400666686 doi "https://doi.org/10.1158/1538-7445.sabcs15-p6-17-01" @default.
• W2400666686 hasPublicationYear "2016" @default.
• W2400666686 type Work @default.
• W2400666686 sameAs 2400666686 @default.
• W2400666686 citedByCount "1" @default.
• W2400666686 countsByYear W24006666862019 @default.
• W2400666686 crossrefType "journal-article" @default.
• W2400666686 hasAuthorship W2400666686A5006757571 @default.
• W2400666686 hasAuthorship W2400666686A5010529280 @default.
• W2400666686 hasAuthorship W2400666686A5021270265 @default.
• W2400666686 hasAuthorship W2400666686A5023674071 @default.
• W2400666686 hasAuthorship W2400666686A5026987682 @default.
• W2400666686 hasAuthorship W2400666686A5043219897 @default.
• W2400666686 hasAuthorship W2400666686A5048774512 @default.
• W2400666686 hasAuthorship W2400666686A5049168429 @default.
• W2400666686 hasAuthorship W2400666686A5049358292 @default.
• W2400666686 hasAuthorship W2400666686A5051465568 @default.
• W2400666686 hasAuthorship W2400666686A5053164536 @default.
• W2400666686 hasAuthorship W2400666686A5058128666 @default.
• W2400666686 hasAuthorship W2400666686A5067203408 @default.
• W2400666686 hasAuthorship W2400666686A5068075658 @default.
• W2400666686 hasAuthorship W2400666686A5089332843 @default.
• W2400666686 hasConcept C121608353 @default.
• W2400666686 hasConcept C126322002 @default.
• W2400666686 hasConcept C143998085 @default.
• W2400666686 hasConcept C207103383 @default.
• W2400666686 hasConcept C2775930923 @default.
• W2400666686 hasConcept C2778527826 @default.
• W2400666686 hasConcept C2908647359 @default.
• W2400666686 hasConcept C44249647 @default.
• W2400666686 hasConcept C50382708 @default.
• W2400666686 hasConcept C530470458 @default.
• W2400666686 hasConcept C71924100 @default.
• W2400666686 hasConcept C99454951 @default.
• W2400666686 hasConceptScore W2400666686C121608353 @default.
• W2400666686 hasConceptScore W2400666686C126322002 @default.
• W2400666686 hasConceptScore W2400666686C143998085 @default.
• W2400666686 hasConceptScore W2400666686C207103383 @default.
• W2400666686 hasConceptScore W2400666686C2775930923 @default.
• W2400666686 hasConceptScore W2400666686C2778527826 @default.
• W2400666686 hasConceptScore W2400666686C2908647359 @default.
• W2400666686 hasConceptScore W2400666686C44249647 @default.
• W2400666686 hasConceptScore W2400666686C50382708 @default.
• W2400666686 hasConceptScore W2400666686C530470458 @default.
• W2400666686 hasConceptScore W2400666686C71924100 @default.
• W2400666686 hasConceptScore W2400666686C99454951 @default.
• W2400666686 hasIssue "4_Supplement" @default.
• W2400666686 hasLocation W24006666861 @default.
• W2400666686 hasOpenAccess W2400666686 @default.
• W2400666686 hasPrimaryLocation W24006666861 @default.
• W2400666686 hasRelatedWork W2109435012 @default.
• W2400666686 hasRelatedWork W2154462701 @default.
• W2400666686 hasRelatedWork W2224319365 @default.
• W2400666686 hasRelatedWork W2603750384 @default.
• W2400666686 hasRelatedWork W2923100037 @default.
• W2400666686 hasRelatedWork W2987985474 @default.
• W2400666686 hasRelatedWork W3092055732 @default.
• W2400666686 hasRelatedWork W3096243511 @default.
• W2400666686 hasRelatedWork W3181412252 @default.
• W2400666686 hasRelatedWork W3202449578 @default.
• W2400666686 hasVolume "76" @default.
• W2400666686 isParatext "false" @default.
• W2400666686 isRetracted "false" @default.
• W2400666686 magId "2400666686" @default.
• W2400666686 workType "article" @default.